Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2012
06/14/2012US20120148535 Oncolytic adenoviruses for treating cancer
06/14/2012US20120148533 Combination therapy
06/14/2012US20120148531 Fused heterocyclic derivatives and methods of use
06/14/2012US20120148529 Use of Inclusion Bodies as Therapeutic Agents
06/14/2012US20120148528 Compositions and methods to induce targeted apoptosis
06/14/2012US20120148527 TNF Superfamily Fusion Proteins
06/14/2012US20120148526 Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
06/14/2012US20120148509 Composition for alleviating ultraviolet irradiation-induced damage
06/14/2012US20120148502 Carbohydrate-Mediated Tumor Targeting
06/14/2012US20120148493 Composite Materials Loaded with Therapeutic and Diagnostic Agents Comprising Polymer Nanoparticles and Polymer Fibers
06/14/2012US20120148491 Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
06/14/2012US20120148490 Anti-ngf compositions and use thereof
06/14/2012CA2821109A1 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
06/14/2012CA2820800A1 Triazole derivatives as wnt signaling pathway inhibitors
06/14/2012CA2820782A1 Bispecific aptamers mediating tumour cell lysis
06/14/2012CA2820748A1 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
06/14/2012CA2820681A1 Use of chimeric antigen receptor-modified t cells to treat cancer
06/14/2012CA2820642A1 Galectin-9-secreting cell, and production method and use of the same
06/14/2012CA2820630A1 Dimeric molecular complexes with free cysteine residues and conjugates thereof
06/14/2012CA2820416A1 New pharmaceutical compositions
06/14/2012CA2820389A1 [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
06/14/2012CA2820384A1 Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
06/14/2012CA2820382A1 Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
06/14/2012CA2820262A1 Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
06/14/2012CA2820245A1 Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
06/14/2012CA2820134A1 Human monoclonal antibody
06/14/2012CA2820114A1 Compound for the treatment of tumours and tumour metastases
06/14/2012CA2820065A1 Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
06/14/2012CA2819955A1 Substituted imidazoquinoline derivatives
06/14/2012CA2819889A1 Substituted pyridinone-pyridinyl compounds
06/14/2012CA2819850A1 Psma-targeted dendrimers
06/14/2012CA2819554A1 Dosage and administration of bispecific scfv conjugates
06/14/2012CA2819130A1 Compositions and methods for mobilizing stem cells
06/14/2012CA2819038A1 Humanized antibodies to liv-1 and use of same to treat cancer
06/14/2012CA2818669A1 Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
06/14/2012CA2818635A1 Antibodies selective for cells presenting erbb2 at high density
06/14/2012CA2818313A1 Anti ccr4 antibodies and uses thereof
06/14/2012CA2816829A1 Triazolopyridine compounds
06/13/2012EP2463381A1 Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer
06/13/2012EP2463299A2 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
06/13/2012EP2463289A1 Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
06/13/2012EP2462951A1 Use of two microrna moleculars in lung cancer prognosis and medicine preparation
06/13/2012EP2462946A1 Method of inhibiting cathepsin activity
06/13/2012EP2462945A2 Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity
06/13/2012EP2462934A1 Anti-tumor activity of temsirolimus in papillary renal cell cancer
06/13/2012EP2462932A1 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
06/13/2012EP2462143A1 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators
06/13/2012EP2462141A1 Novel azaheterocyclic compounds
06/13/2012EP2462128A2 Compounds as lysophosphatidic acid receptor antagonists
06/13/2012EP2462117A1 Quinolinyloxyphenylsulfonamides
06/13/2012EP2461870A1 Therapeutic compositions and methods
06/13/2012EP2461869A1 Novel bicyclic urea compounds
06/13/2012EP2461814A2 Treatment of prostate cancer
06/13/2012EP2461813A1 Compositions and methods for inducing apoptosis in prostate cancer cells
06/13/2012EP2461810A1 Methods of using c-met modulators
06/13/2012EP2461806A2 Antiangiogenic small molecules and methods of use
06/13/2012EP2461683A1 Bicyclic aryl sphingosine 1-phosphate analogs
06/13/2012EP2252373B1 Novel fer -like protein, pharmaceutical compositions containing it and method for its use
06/13/2012EP2175888B1 Radiopharmaceutical compositions comprising polysaccharides grafted by polyamines
06/13/2012EP1989205B1 Thiophene-carboxamides useful as inhibitors of protein kinases
06/13/2012EP1912973B1 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
06/13/2012EP1812570B1 Improved treatment of cancer using tlr3 agonists
06/13/2012EP1809629B1 N,N'-diphenyl urea derivatives suitable for the treatment of tumours, eye diseases, inflammation and diseases of the immune system
06/13/2012EP1798234B1 Pharmaceutical composition comprising temozolomide ester
06/13/2012EP1797038B1 Thermodynamically stable form of bay 43-9006 tosylate
06/13/2012EP1774976B1 Malignant tumor local infiltration inhibitor containing batroxobin
06/13/2012EP1734944B1 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
06/13/2012EP1699460B1 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
06/13/2012EP1613273B1 Recombinant il-9 antibodies and uses thereof
06/13/2012EP1495053B1 Angiopoietin-2 and angiopoietin-1 specific binding agents
06/13/2012EP1490110B1 Anti-alpha v beta 6 antibodies
06/13/2012EP1459070B1 Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers
06/13/2012EP1414471B1 Therapeutic agents comprising pro-apoptotic proteins
06/13/2012EP1355666B1 Use of repulsive guidance molecule (RGM) and its modulators
06/13/2012EP1297017B1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
06/13/2012CN1898212B Analogs of benzoquinone-containing ansamycins for the treatment of cancer
06/13/2012CN1743337B Taxol derivative and its pharmaceutical composition
06/13/2012CN102498211A Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof
06/13/2012CN102498129A Inhibition of tumor metastasis using bv8- or g-csf-antagonists
06/13/2012CN102498115A Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
06/13/2012CN102498114A Compounds as tyrosine kinase modulators
06/13/2012CN102498113A Macrocyclic inhibitors of jak
06/13/2012CN102498111A Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
06/13/2012CN102498110A 2- (LH-pyrazol-4-ylamino) -pyrimidine as kinase inhibitors
06/13/2012CN102497872A Inhibitor of inflammatory conditions
06/13/2012CN102497871A Extracellular matrix compositions for the treatment of cancer
06/13/2012CN102497862A Combination therapies with ck2 modulators
06/13/2012CN102492051A Polygonatum odoratum deep processing and comprehensive utilization process
06/13/2012CN102492043A Anti-tumor and thrombolytic dual-effect chimeric protein with low immunogenicity, its preparation method and application
06/13/2012CN102492039A Fully humanized antihuman HER2 monoclonal antibody
06/13/2012CN102492038A Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
06/13/2012CN102492023A PLAC1 anti-tumour CTL epitope peptide and application thereof
06/13/2012CN102492014A Preparation method of tanshinone IIA tocopheryl acid phenolic ester derivative
06/13/2012CN102492010A Derivatives of camptothecin 20-site bile acid and preparation method thereof
06/13/2012CN102492009A Camptothecin 20- position cholic acid derivative and preparation method thereof
06/13/2012CN102492006A Canthaxanthin compound and application of compound to preparation of antitumor drugs
06/13/2012CN102491997A Cholic acid-molybdenum polyoxometallate-cholic acid compound and synthetic method
06/13/2012CN102491981A Amphiphilic anti-cancer drug compound modified by water-soluble vitamin E derivative, preparation, preparation method and application for compound
06/13/2012CN102491979A 1-hydroxyethyl-5-substituted indolone derivative and preparation method and application thereof
06/13/2012CN102491978A Method for preparing natural pigments, polysaccharide and saponin by utilizing disused asparagus resources
1 ... 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 ... 2211